To assess the prognostic value of sex differences in upper tract urothelial carcinoma (UTUC) and urothelial carcinoma in bladder (UCB) treated with radical surgery.
The PUBMED, Web of Science, Cochrane Library, and Scopus databases were searched in July 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared overall, cancer-specific, and recurrence-free survival in UTUC and UCB patients. Formal meta-analyses were performed for these outcomes according to sex differences.
66 studies with 100,389 UCB patients and 40 studies with 39,759 UTUC patients were eligible for review and meta-analysis. Females in UCB were associated with worse cancer-specific survival (pooled hazard ratio [HR]: 1.20, 95% confidence interval [CI]: 1.10-1.31), overall survival (pooled HR: 1.03, 95% CI: 1.01-1.05), and recurrence-free survival (pooled HR: 1.13, 95% CI: 1.02-1.25). In contrast, those in UTUC were not associated with cancer-specific survival (pooled HR: 0.94, 95% CI: 0.89-1.00), overall survival (pooled HR: 0.98, 95% CI: 0.95-1.01), and recurrence-free survival (pooled HR: 0.90, 95% CI: 0.78-1.03).
Sex is shown to be associated with cancer-specific mortality, overall mortality, and disease recurrence in UCB but not in UTUC. Given the genetic and social differences between sex, sex differences may represent a key factor in the clinical decision-making process.
The Journal of urology. 2020 Jan 29 [Epub ahead of print]
Keiichiro Mori, Hadi Mostafaei, Dmitry V Enikeev, Ivan Lysenko, Fahad Quhal, Shoji Kimura, Pierre I Karakiewicz, Shin Egawa, Shahrokh F Shariat
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia., Department of Urology, The Jikei University School of Medicine, Tokyo, Japan., Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.